Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman

RTTNews | 783 days ago
Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman

(RTTNews) - Biopharmaceutical company Protalix BioTherapeutics, Inc. (PLX) announced Tuesday that the Company's Board of Directors has appointed Eliot Richard Forster to serve on the Board of Directors as its Chairman, effective as of September 14, 2023.

In addition to Forster's appointment as Chairman and an independent director, he was also appointed to serve on the Company's Nominating Committee. Zeev Bronfeld, the current Chairman of the Company's Board of Directors, will retire on the same day.

Forster currently serves as the Non-Executive Chairman of Avacta Group PLC (AVCT), as a Non-Executive Director of Immatics NV (IMTX) and as the Non-Executive Chairman of Ochre Bio, Inc., a private biotechnology company.

Forster served as the Chief Executive Officer of F-Star Therapeutics Ltd., a clinical-stage bispecific antibodies company, until its March 2023 sale to inovoX Ltd. Prior to that, he served as CEO of Immunocure Ltd., CEO of Creabilis SA and President and CEO of Solace Pharmaceuticals Inc., each of which was a privately-held life science company.

Earlier in his career, he held positions at Pfizer Global Research & Development and Glaxo/GlaxoWellcome.

read more
Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease

Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease

Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.
RTTNews | 983 days ago
Australia Keeps Interest Rate Unchanged

Australia Keeps Interest Rate Unchanged

The Reserve Bank of Australia maintained its key interest rate as the full effects of earlier rate cuts are yet to be felt and policymakers became cautious after data showed evidence of more persistent inflation. The policy board governed by Michele Bullock decided to hold the cash rate at 3.60 percent, as widely expected, on Tuesday.
RTTNews | 1h 15min ago
European Shares Seen Lower As US Economic Concerns Mount

European Shares Seen Lower As US Economic Concerns Mount

European stocks are seen opening on a sluggish note Tuesday as weak U.S. manufacturing data raised concerns about a slowing U.S. economy and mixed comments from Federal Reserve officials dampened hopes for a December rate cut.
RTTNews | 2h 13min ago
Australian Market Extends Early Losses In Mid-market

Australian Market Extends Early Losses In Mid-market

The Australian stock market is extending its early losses in mid-market trading on Tuesday, reversing the gains in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling well below the 8,850 level, with weakness in iron ore miners, financial, energy and technology stocks partially offset by gains in gold miners and stocks.
RTTNews | 4h 26min ago
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian stock markets are trading mixed on Tuesday, following the mixed cues from Wall Street overnight, as traders have been reluctant to make more significant moves ahead of the release of US payroll processor ADP's report on private sector employment on Wednesday. A survey showed economic activity in the U.S. manufacturing sector contracted in October for the eighth consecutive month.
RTTNews | 4h 53min ago
Sensex, Nifty Seen Flat To Lower At Open

Sensex, Nifty Seen Flat To Lower At Open

Indian shares are seen opening flat to slightly lower on Tuesday after Federal Reserve officials offered mixed signals about future rate cuts.
RTTNews | 5h 21min ago